Locations:
Search IconSearch
December 19, 2022/Cancer

Tranexamic Acid Offers Better Control of Heavy Menstrual Bleeding in Patients with Von Willebrand Disease

Multi-site study reveals surprising findings

Pads

Von Willebrand disease (VWD) is the most common inherited bleeding disorder in the world, and heavy menstrual bleeding affects as many as 80% of women and girls with the condition. Yet there is no consensus on the optimal treatment approach. Now a new multi-institution study compares two treatment options.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The study looked at recombinant Von Willebrand factor, which works by replacing deficient Von Willebrand protein and has been shown to safely reduce bleeds in patients but has not been studied in treating heavy menstrual bleeding specifically. It was compared against tranexamic acid, an anti-fibrinolytic medication that’s one of the standard non-hormonal treatments for VWD.

“The hypothesis of the trial designers was that the recombinant Von Willebrand may be better, but actually the results were the opposite,” says Dana Angelini, MD, a physician in Cleveland Clinic’s Hematology and Medical Oncology department and a coauthor on the study. Researchers found that tranexamic acid was significantly more effective at controlling heavy menstrual bleeding. It also reduced the frequency of flooding reported by participating women. There was no difference between the two treatments when it came to cycle severity, cycle length and reported quality of life.

The paper, “Multicenter, Randomized Crossover Trial Comparing Recombinant Von Willebrand Factor and Tranexamic Acid for Heavy Menstrual Bleeding in Von Willebrand Disease,” was presented at the 2022 American Society of Hematology meeting. Cleveland Clinic participated in the study, which was designed by researchers at the University of Pittsburgh.

Unmet need for treatment options

Dr. Angelini noted that there is an unmet need for better treatments for VWD, and the issue of menses in particular is under studied. Some treatments are not well tolerated by patients, while others that involve the use of contraceptives may not be an option for patients trying to get pregnant. “Outside of oral hormonal treatment, there really isn’t a standard of how to approach heavy menstrual bleeding in these patients,” she says.

Advertisement

For the randomized, crossover study, 36 women with VWD were split into two groups. Half received tranexamic acid, while the other half received recombinant VWF. After two cycles, patients switched to the other treatment.

Each woman kept a diary to record their flow and other symptoms, using a pictorial blood assessment chart to measure their flow. “Even with Von Willebrand disease, menstrual flow varies so much from woman to woman, so using each woman as her own control allowed researchers to assess the outcomes with better clarity,” says Dr. Angelini.

“Having data in this field is great, no matter what the result,” Angelini says. “This was a good trial that helped answer an important question, and the results can help guide treatment decisions when physicians are talking through options with patients.”

Advertisement

Related Articles

Woman's hands holding sanitary napkin
A Clinician’s Guide to Improve Access to Menstrual Healthcare and Support Better Outcomes

Approximately 500 million people globally are experiencing 'period poverty'

Dr. Holubar in surgery
May 12, 2025/Digestive/Research
New Study Highlights LMWH's Role in Lowering VTE Incidence After IBD Surgery

Findings help close the knowledge gap around VTE practice patterns

Foot examination
April 24, 2025/Primary Care/Case Study
Case Study: A 74-Year-Old Woman With Purple Toes

Confounding symptoms and a complex medical history prove diagnostically challenging

Young woman on scale
Recognizing Eating Disorders in Youth: When Menstrual Dysfunction Is a Clue

Pediatric and adolescent reproductive providers are uniquely positioned to intervene

Blood clot
May 17, 2024/Cancer/Research
Managing the Risks of Venous Thromboembolisms in Patients with Cancer

Oral anticoagulants may be beneficial but need to be balanced against bleeding risks

23-NEU-4479131-thrombolysis-ischemic-stroke-650×450
Thrombolytics Compared in Large Vessel Occlusion Patients Undergoing Mechanical Thrombectomy

Higher complete reperfusion rate seen with tenecteplase vs. alteplase in single-center study of stroke with LVO

23-HVI-4400491 CQD 650×450
Low-Dose Aspirin Slows Abdominal Aortic Aneurysm Progression

Large cohort study finds significant effect in men and nonsmokers

celiac disease
October 24, 2023/Digestive/Research
Women’s Health Disorders Found More Frequently Among Individuals With Celiac Disease

Findings reinforce the importance of multidisciplinary care

Ad